Adagrasib (1, MRTX849; Krazati), a potent and selective KRAS inhibitor of the RAS GTPase family, was developed by Mirati Therapeutics as an anticancer compound to treat non-small cell lung cancer (NSCLC). This evidence concerns the gene KRAS and non-small cell lung carcinoma.